PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Res. Author manuscript; available in PMC 2010 April 26.
Published in final edited form as:
PMCID: PMC2859318
NIHMSID: NIHMS188281

Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells

Abstract

Solid tumor metastasis often involves detachment of epithelial carcinoma cells into the vasculature or lymphatics. However, most studies of cytoskeletal rearrangement in solid tumors focus on attached cells. In this study, we report for the first time that human breast tumor cells produce unique tubulin-based protrusions when detached from extracellular matrix. Tumor cell lines of high metastatic potential show significantly increased extension and frequency of microtubule protrusions, which we have termed tubulin microtentacles (mcTN). Our previous studies in nontumorigenic mammary epithelial cells showed that such detachment-induced microtentacles are enriched in detyrosinated α-tubulin. However, amounts of detyrosinated tubulin were similar in breast tumor cell lines, despite varying microtentacle levels. Since detyrosinated α-tubulin associates strongly with intermediate filament proteins, we examined the contribution of cytokeratin and vimentin filaments to tumor cell microtentacles. Increased microtentacle frequency and extension correlated strongly with loss of cytokeratin expression and upregulation of vimentin, as is often observed during tumor progression. Moreover, vimentin filaments coaligned with microtentacles, while cytokeratin did not. Disruption of vimentin with PP1/PP2A-specific inhibitors significantly reduced microtentacles and inhibited cell reattachment to extracellular matrix. Furthermore, expression of a dominant negative vimentin mutant disrupted endogenous vimentin filaments and significantly reduced microtentacles, providing specific genetic evidence that vimentin supports microtentacles. Our results define a novel model in which coordination of vimentin and detyrosinated microtubules provides structural support for the extensive microtentacles observed in detached tumor cells and a possible mechanism to promote successful metastatic spread.

Introduction

Successful tumor cell colonization in distant tissues depends on overcoming the selective pressures that are imposed on tumor cells during metastasis (1). Such pressures often select for signaling pathways that support tumor cell survival, motility, invasion, and proliferation following release from the primary tumor site (24). Under normal conditions, detachment and dissemination of epithelial carcinoma cells into the microvasculature result in apoptosis or necrosis by shearing forces in narrow capillaries (5, 6). However, metastatic tumor cells are able to persist through adapted signaling pathways and can tolerate the morphological alterations in cell shape, plasticity, and deformation that are necessary to re-adhere and extravasate into distant sites (79).

Growing evidence has necessitated a re-evaluation of the functional implications that stable microtubules (MT) have in tumor metastasis. We previously reported observations of extensive and motile, MT-enriched membrane protrusions in detached mouse and human mammary epithelial cells, which promote cell-cell adherence as well as reattachment to uncoated and ECM-coated culture surfaces (10). These protrusions are mechanistically-distinct from actin-based invadopodia, filopodia and cilia, and have been termed tubulin microtentacles (mcTN) (10). MT-destabilizing agents significantly reduced the frequency with which microtentacles were observed, and impaired both cell-cell interaction and reattachment of cells to surfaces. Interestingly, MT-destabilizing drugs prevent circulating colon carcinoma cells from attaching to the microvascular endothelium in vivo, although the precise mechanism is currently unclear (11). Strikingly, actin depolymerization significantly increases binding of circulating tumor cells to the vascular endothelium (11), and also strongly promotes the extension of tubulin microtentacles (10).

The stability of MTs is influenced by the reversible post-translational cleavage of the COOH-terminal tyrosine of full-length α-tubulin, which is termed tyrosinated tubulin (Tyr-tubulin) (12). Through the action of a yet-unidentifed carboxypeptidase, this tyrosine can be removed rapidly in vivo, exposing a COOH-terminal glutamic acid residue and forming detyrosinated α-tubulin (Glu-tubulin)(13). Importantly, poor patient prognosis correlates with elevated levels of Glu-tubulin in breast tumors (14), neuroblastomas (15), and prostate tumors (16), but the mechanism by which increased Glu-tubulin affects tumor progression is currently unknown. We have shown that Glu-tubulin levels significantly increase following epithelial cell detachment, and detachment-induced microtentacles are enriched in Glu-tubulin (10). Cytoplasmic microtubules enriched in Glu-tubulin persist for as long as 16h, while microtubules enriched in Tyr-tubulin generally turn over within minutes (13). However, detyrosination does not directly stabilize tubulin polymers, as Tyr-tubulin and Glu-tubulin polymerize identically in vitro (17). Rather, detyrosinated MT associate preferentially with more resilient cytoskeletal components (18), such as the vimentin intermediate filament (IF). This candidate type III IF protein displays anterograde movement toward the plus-ends of MTs (19). Light and electron microscopy also demonstrate that IFs and MTs run parallel in close proximity (20).

Given our recent findings that nontumorigenic mammary epithelial cells display tubulin microtentacles following detachment (10), we explored the occurrence of MT-based microtentacles and MT-associated cytoskeletal proteins in a panel of human breast carcinoma cells. We report for the first time that vimentin-expressing, invasive breast carcinomas display a comparatively higher frequency of tubulin microtentacles following detachment than non-vimentin expressing, non-invasive cell lines. Microtentacle preservation following detachment indicates that vimentin coaligns with Glu-tubulin in microtentacles, while cytokeratin does not. Time-lapse video shows that membrane microtentacles are rapidly disrupted by treatment with PP1/PP2A inhibitors that disassemble vimentin, decreasing microtentacle frequency and impairing reattachment of vimentin-expressing tumor cells. Finally, a dominant-negative vimentin mutant disrupts endogenous vimentin filaments and reduces microtentacles, demonstrating a direct role for vimentin assembly in the mechanism underlying breast tumor microtentacles.

Materials and Methods

Cell Culture

MCF10A human mammary epithelial cells of low passage were grown in DMEM/F12 (Gibco) supplemented with 5% horse serum, insulin (5μg/ml), EGF (20ng/ml), hydrocortisone (500ng/ml). SkBr3, Bt20, MDA-468, Hs578t, MDA-MB-436 were maintained in DMEM (Gibco) while ZR75-1 and HCC1395 were maintained in RPMI (Gibco), both supplemented with 10% bovine calf serum at 37°C in 5% CO2. MDA-MB-157 were maintained in L-15 (Gibco) supplemented with 10% fetal bovine serum (FBS) at 37°C without CO2. TIB-131 hybridoma cells that secrete a PAN-intermediate filament antibody (21) were maintained in DMEM supplemented with 10% hybridoma-qualified FBS, sodium pyruvate (1.0mM) at 37°C in 10% CO2. Sequential adaptation in Hybridoma Serum-Free media (Gibco) was used to subculture cells to minimal serum level for antibody isolation. All cell lines were obtained by American Type Culture Collection (Manassas, VA), and all media was supplemented with penicillin-streptomycin(100 μg/ml each), and L-glutamine (2 mmol/L).

Vimentin Expression Constructs and Transfection

Human vimentin was cloned into the N-terminal eGFP pReceiver-M29 expression vector (Genecopoeia, Germantown, MD). The truncated vimentin was generated by restriction at the internal vimentin Xho I site (position 403) and re-ligating the 5′ overhang with a flanking XhoI site at the C-terminal multiple cloning site. Both the full-length and truncated vimentin were separated on a gel and sequenced.

Transient transfections of membrane targeted AcGFP1-Mem (Clontech, Mountain View, CA) and CMV-pmRFP-Mem (kindly provided by Georges Luftalla and previously described (22)) were used to visualize and score membrane microtentacles in suspended cells via fluorescent microscopy. Co-transfections were performed with the pmRFP-Mem and the N-GFP vimentin constructs in a 1:1 DNA ratio. MCF10A, SkBr3, Bt20, MDA-MB-157 cells were transfected according to manufacturer’s protocol with FuGENEHD transfection reagent (Roche, Branchburg, NJ) using a complex ratio of 3μl of FuGENEHD to 2μg of DNA. ZR75-1, HCC1395, MDA-468, Hs578t, and MDA-MB-436 cells were transfected with Exgen500 (Fermentas, Glen Burnie, MD) using complex ratio of 5.3μl of Exgen500 to 2μg of DNA.

Validated double-stranded siRNA oligonucleotides for human vimentin (5′-CTGGCACGTCTTGACCTTGAA- 3′) and a conjugated Alexa Fluor 488 non-silencing control were purchased from Qiagen (Germany). MDA-MB-436 cells were transfected with HiPerfect (Qiagen, Germany) with 5nM of siRNA. Western blot analysis and immunofluorescence was performed 4, 5, 6d post-transfection. For microtentacle scoring at 6d post siRNA transfection, MDA-MB-436 cells were split 4d post-transfection into optimal confluency conditions for GFP-Mem transfection.

Live Cell Imaging and Membrane Microtentacle Scoring

Cells were trypsinzed at ~80% confluency after 24h expression and resuspended in serum/phenol red (PR)-free media over ultra-low attachment plates in the presence or absence of 5μM Latrunculin-A (LA) (BioMol, Plymouth Meeting, PA) for 1h. For microtentacle scoring involving phosphatase inhibitor treatment, MCF10A and MDA-MB-436 were pretreated with either 1μM okadiac acid (OKA) (Sigma, St. Louis, MO) or 5nM Calyculin-A (CAL-A) (Chemicon, Billerica, MA) in serum-containing media for 1h and resuspended in serum/(PR)-free media in the respective phosphatase inhibitor with or without 5μM Latrunculin-A.

Single cells were scored blindly for microtentacles at 1h in suspension and GFP+ cells were photographed by fluorescent microscopy. Cells with two or more microtentacles extending greater than the radius of the cell body were scored as positive. Populations of 100 or more GFP+ cells were counted for each trial. Live and fixed cell images were collected using an Olympus CKX41 inverted fluorescent microscope (Melville, NY) equipped with the Olympus F-View II 12-bit CCD digital camera system and Olympus MicroSuite Five imaging software. Movies of detached cells were captured at one frame every two seconds and are shown with a 5× acceleration.

Differential interference contrast (DIC) images of MDA-MB-436 cells suspended over 35 mm glass bottom dishes (MatTek, Ashland, MA) were acquired using a Zeiss Axiovert 200M motorized microscope equipped with a stage-enclosed incubation system (Incubator XL-3, PeCon, Erbach, Germany). Cells were incubated at 37°C for 10min to allow for transient attachment to anchor cells. Cells that displayed active membrane microtentacles were selected for imaging. Selected cells were imaged over time pre-and post-treament with 1μm OKA or 5nM Cal-A. 3D image stacks were acquired every 3 min for up to 45 min. Zeiss Axiovision software was used for image acquisition and cropping.

Immunofluorescence

To determine cytoskeletal composition of microtentacles observed in suspension, MCF10A and MDA-MB-436 cells were suspended in serum/PR-free media for 30min in the presence or absence 5μM Latrunculin-A. Cells were then fixed in suspension (0.5% glutaraldehyde, 5min.) and gently spun (200rpm, 5min.) onto glass coverslips coated with 1% poly(ethyleneimine) (PEI) solution. Fixative-containing media was aspirated and autofluorescene was quenched using 1mg/ml sodium borohydride solution. For attached cell experiments, MCF10A and MDA-MB-436 on glass coverslips were treated with either 1μM OKA or 5nM Cal-A in serum-free media for 1h at ~80% confluency. Cells were fixed in 3.7% formaldehyde/PBS (10 min., R.T.).

Fixed cells were permeablized (0.25% Triton X-100/PBS, 10 min.), and blocked for 1hr (PBS/5% BSA/0.5% NP40). Immunostaining was performed using mouse monoclonal antibodies vimentin clone V9 (1:1000; Zymed) and PAN cytokeratin clone AE1/AE3 (1:1000; Zymed), and rabbit polyclonal anti-detyrosinated tubulin (Glu; 1:500; Chemicon). Primary incubation was performed overnight at 4°C (PBS/2% BSA/0.5% NP40). Anti-IgG antibodies conjugated to Alexa-594 and Alexa-488 (1:1000; Molecular Probes) were used for secondary detection and Hoescht 33342 (1:5000; Sigma) was used for nuclear staining.

Western Blot

The panel of confluent, untreated cells or specifically, MCF10A and MDA-MB-436 treated in serum/PR-free media at various timepoints in 1μM OKA, 5nM Cal-A, or 30ug/ml cycloheximide were harvested in ice-cold RIPA lysis buffer (50mM Tris-HCl (pH 8.0), 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM phenylmethylsulfonyl fluoride, 1% protease inhibitor cocktail (Sigma, P2714). Lysates were subjected to high-speed centrifugation (14000rpm × 10min) and protein concentration was measured using a Lowry-based assay (Bio-Rad, Hercules, CA). 20μg of total protein was separated by SDS-PAGE on 10% polyacrylamide gels and then transferred to Immuno-Blot PVDF membranes (Bio-Rad, Hercules, CA). Membranes were blocked in 5% milk in TBS with 0.1% Tween for 1hr at room temperature followed by an overnight incubation at 4°C in monoclonal α-tubulin (1:1000; Sigma Chemical), PAN cytokeratin clone AE1/AE3 (1:1000; Zymed), and polyclonal detyrosinated tubulin (1:1000; Chemicon), Vimentin (C-20, Santa Cruz Biotechnology; 1:1000), Vimentin (H-84, Santa Cruz Biotechnology; 1:1000), and PARP (H-250, Santa Cruz Biotechnology; 1:1000), in 2.5% milk in TBST. Monoclonal PAN-IF isolated from TIB-131 hybridoma cells (1:250) was incubated overnight in 5% milk in TBST. Secondary antibodies to IgG conjugated to horseradish peroxidase were used (1:5000; GE Healthcare, Piscataway, NJ) and visualized using ECL+ chemiluminescent detection kit.

Attachment Assay

MCF10A and MDA-MB-436 cells were grown to confluency in 6-well plates and pretreated in either 1μM OKA or 5nM Cal-A in serum-containing media for 1h. Media and subsequent PBS wash were collected to recover all cells. Cells were trypsinized and resuspended in serum-containing media, collected into respective tube, and pelleted by centrifugation (1000rpm × 5min). Media was aspirated from pellet and cells were gently triturated in fresh serum-containing media containing 1μM OKA or 5nM Cal-A. Cells plated in triplicate in 96-well clear bottom uncoated or laminin-coated (BD Biosciences, San Jose, CA) plates (the attachment plate). Cells were allowed to attach for duration of 15 min, 45 min, 1.5 hr, 3hr, 4hr, 6hr, and 24hr at which point the media was collected into a fresh 96-well uncoated plate (the collection plate). The attachment plate was washed gently with fresh serum-containing growth media without PR and the wash was combined into the collection plate. Fresh growth media was replaced at each timepoint on the original attachment plate. After 24hr, an XTT viability assay was performed on both the attachment and collection plate to quantitatively determine the % of total number of cells plated that had attached at each timepoint. Absorbance was measured using a Biotek Synergy HT Multi-Detection Microplate Reader at 450nm. All values are shown as mean+S.D. of triplicate samples.

Results

Human mammary carcinoma cell lines display morphologically different membrane microtentacles following detachment

We compared the tubulin microtentacles observed in the nontumorigenic MCF10A human mammary epithelial cell line (10), to those in a panel of human breast tumor cell lines. GFP-Mem+ cell lines were detached and suspended over ultra-low attachment plates in media deprived of serum and growth factors. Grayscale images collected with fluorescence microscopy were subsequently color inverted for better visualization contrast. Detachment of invasive breast tumor cell lines: Hs578t, HCC1395, MDA-MB-436 and MDA-MB-157 produced unusually long, semi-flexible, and motile microtentacles compared to noninvasive MCF10A, ZR-75-1, Bt-20, SkBr3 and MDA-MB-468 lines, which display relatively short, rigid, and semi-motile microtentacles (Figure 1A and Supplemental Movies 13). Our previous research has shown that inhibiting actin polymerization with Latrunculin-A (LA, 5μM) enhances microtentacle frequency, motility and length in both human and mouse mammary epithelial cells following detachment (10). LA similarly increases the length, flexibility and motility of microtentacles in breast tumor cells (Figure 1B and Supplemental Movies 46). However, the invasive breast tumor cell lines were clearly able to form dynamic and flexible microtentacles even in the absence of LA treatment. Blinded scoring of microtentacle frequencies (described in Materials and Methods) was conducted in live cells following 30min to 1h in suspension for each of 4 independent trials. Invasive breast tumor cell lines (Hs578t, HCC1395, MDA-MB-436 and MDA-MB-157) all displayed significantly higher microtentacle frequencies (P<0.05, t-test) than the noninvasive breast tumor cell lines (Zr-75-1, Bt-20, SkBr3 and MDA-MB-468) or nontumorigenic MCF10A cells (Figure 1C). Microtentacles in both untreated and LA-treated human carcinoma cells can persist at least 48h (data not shown), while MCF10A cells are highly fragmented by late stage apoptosis after 48h of detachment (10).

Fig. 1
Microtentacles in detached human breast tumor cell lines

Vimentin expressing cell lines have more frequent and extensive tubulin microtentacles

While we previously reported that microtentacles are enriched in detyrosinated (Glu) α-tubulin (10), we did not observe significant differences in Glu-tubulin modification or total cellular expression of α-tubulin in the panel of breast tumor cell lines (Figure 1D). These data indicated that Glu-tubulin alone may not account for such distinct morphologies and increased microtentacle frequency in these cell lines. Since microtubules interact with intermediate filaments, we examined cytokeratin and vimentin expression in these cell lines. Western blot analysis (Figure 1D) and indirect immunofluorescence (data not shown) confirmed that non-invasive, epithelioid cell lines ZR-75-1, Bt-20, SkBr3 and MDA-MB-468 homogeneously expressed cytokeratin and not vimentin while moderate- to highly-invasive, fibroblastioid-like cell lines Hs578t, HCC1395, MDA-MB-436 and MDA-MB-157 cells homogeneously expressed vimentin and not cytokeratin. Non-tumorigenic human mammary epithelial cell line MCF10A displayed heterogeneous expression of both vimentin and cytokeratin, with cytokeratin being the dominating intermediate filament in cell monolayers and pronounced vimentin expression at monolayer edges (data not shown). Expression of vimentin is much higher in breast tumor cells which display long and numerous microtentacles, while cytokeratin expression predominated in those cell lines that displayed fewer and shorter microtentacles (Figure 1D).

Vimentin extends into microtentacles

Given the correlation of vimentin expression in those cells that exhibit more extensive and frequent microtentacles, we examined intermediate filament localization with indirect immunofluorescence, finding that vimentin, and not cytokeratin, extends into microtentacles (Figure 2). MCF10A and MDA-MB-436 were used for this and all subsequent experiments, due to the extensive microtentacles of the invasive MDA-MB-436 human carcinoma cell line and the fact that MCF10A cells express both cytokeratin and vimentin. Detached cells were fixed after 30min in suspension in the presence or absence of 5μM LA and centrifuged at low speed onto PEI-coated coverslips to preserve suspended cell architecture for immunofluorescence analysis. LA-treatment enhanced the protrusive effect for immunofluoresence processing as previously described (10). Staining with antibodies against vimentin and a PAN cytokeratin reveal that vimentin is present in microtentacles while cytokeratin is limited to the cell body in MCF10A and weakly diffuse in MDA-MB-436 (Figure 2). Subsequent immunofluorescence of preserved detached cells shows that vimentin and Glu-tubulin co-align in microtentacles of untreated and LA-treated cells suggesting that vimentin may serve to reinforce Glu-tubulin in microtentacles (Figure 3). Extension of microtentacles throughout 3-dimensional space provides challenges to imaging, but confocal imaging allows exclusion of out-of-focus light in rounded cells and highlights the extension of vimentin in microtentacles (Figure 3B).

Fig. 2
Vimentin, not cytokeratin, is localized to membrane microtentacles
Fig. 3
Vimentin aligns with Glu-tubulin in membrane microtentacles

Disruption of vimentin by phosphatase inhibitors decreases microtentacles

To determine effects of vimentin disruption on morphology and microtentacle frequency, we used two highly selective PP1/PP2A inhibitors that disassemble vimentin IFs via phosphorylation, okadaic acid (OKA, 1μM) and calyculin-A (Cal-A, 5nM),(23, 24). MCF10A and MDA-MB-436 lose vimentin organization after treatment with OKA or Cal-A for 1h (Figure 4A). Under normal growth conditions, MCF10A heterogeneously express vimentin in the cell population with intact vimentin extending to the cell periphery (Figure 4A-A). MDA-MB-436 under normal growth conditions homogenously expresses vimentin that extends to the cell periphery with homogenous expression in the cell population (Figure 4A–E). Both cell lines project vimentin filaments from a perinuclear region with concentrated vimentin. Calyculin-A treatment caused fragmentation and a decrease in vimentin that extended to the cell periphery in MCF10A (Figure 4A–B) while a more pronounced effect in MDA-MB-436 was observed with cell rounding, vimentin fragmentation, and reorganization around the center of the cell body (Figure 4A–F). Treatment with OKA resulted in a more dramatic change in vimentin morphology than Cal-A in MCF10A cells marked by cell rounding and vimentin fragmentation (Figure 4A–D). MDA-MB-436 displayed similar morphological changes with OKA as seen with Cal-A with a slight increase in retraction of the vimentin network to the perinuclear region (Figure 4A–H). Control staining in the absence of serum did not cause noticeable effects on vimentin organization (Figure 4A–B and 4A–F).

Fig. 4
Inhibitors of PP1/PP2A disrupt vimentin without toxicity

To exclude toxicity as a cause for vimentin disruption following Cal-A or OKA treatment, apoptosis was measured by PARP cleavage in MCF10A and MDA-MB-436 cells. No significant PARP cleavage occurred in either MCF10A and MDA-MB-436, even after 6h in Cal-A or OKA (Figure 4B). MCF10A cells remain sensitive to cycloheximide-induced apoptosis, while MDA-MB-436 cells are resistant. An XTT viability assay was performed to confirm that the treatments did not cause apoptosis-independent cell death out to 24h (Figure 4C).

GFP-Mem MCF10A and MDA-MB-436 were pretreated with either Cal-A or OKA for 1h to disrupt vimentin organization, and then suspended in the presence of the corresponding pretreatment for 1h with or without the addition of LA. Blind microtentacle scoring in 3 independent trials demonstrated a significant decrease in microtentacle frequency over the untreated control (P<0.05, t-test) following vimentin disruption by OKA and Cal-A (Figure 5A) in both MCF10A and MDA-MB-436. LA-enhanced microtentacles are also significantly reduced by combination treatment with OKA+LA or Cal-A+LA (P<0.05, t-test).

Fig. 5
Vimentin disassembly with PP1/PP2A inhibitors reduces microtentacles and attachment

Time-lapse DIC video microscopy shows that untreated MDA-MB-436 cells continue to produce active microtentacles when transiently attached to glass coverslips. The addition of either OKA or Cal-A reduced microtentacle motility and caused retraction approximately 30min post-treatment (Figure 5B, Supplemental Data Movies 7 & 8). These results further indicate that the stability and motion of microtentacles can be inhibited by compounds that affect vimentin phosphorylation.

Disruption of vimentin impairs attachment of vimentin expressing cell lines

Given the role of micotentacles in the reattachment of suspended cells (10), we examined whether vimentin disruption with OKA and Cal-A would also affect reattachment. MCF10A and MDA-MB-436 were pretreated for 1h in OKA or Cal-A, then resuspended in same treatment over uncoated (N=3) or laminin (N=3) tissue culture plates and assessed for cell reattachment. Plots of individual trials (conducted in triplicate) are represented in Figure 5C but the same trend was observed in all trials conducted (Supplemental Figure 1 and 2).

While MCF10A attachment efficiency to either uncoated or laminin-coated surfaces was not significantly affected by Cal-A treatment, attachment was significantly sensitive to treatment with OKA (Figure 6A). This result matches the less-pronounced vimentin disruption in MCF10A cells after Cal-A, as compared to OKA (Figure 4A–B & 4A–D). Interestingly, MDA-MB-436 attachment was significantly impaired by the presence of either Cal-A or OKA (Figure 5C). MDA-MB-436 attachment to uncoated surfaces was impaired (to a greater degree) more significantly at earlier timepoints (15min to 3h) than over laminin at the same early timepoints. The delay in attachment of untreated MDA-MB-436 cells to laminin at early timepoints (15min–1.5h) compared to uncoated plates suggests that a possible adjustment time period is necessary for MDA-MB-436 cells to begin forming permanent attachments and spreading. Cells can become independent of immobilized ECM coatings by depositing new ECM molecules, expressing different ECM receptors, or increasing the ECM receptors (25). Microtentacle-mediated reattachment of suspended cells to ECM in vitro (10) is therefore inhibited by compounds that affect vimentin assembly, and cells expressing high levels of vimentin, such as MDA-MB-436, are comparatively more sensitive to these compounds, potentially indicating a greater dependence of these cell lines on the expressed vimentin.

Fig. 6
Dominant negative vimentin (Vim-DN) disrupts filaments and reduces microtentacles

Dominant negative vimentin mutant inhibits filament assembly and reduces microtentacles

To determine if vimentin directly supports the mechanism underlying microtentacles, we generated a dominant-negative vimentin mutant. With guidance from studies of both in vitro vimentin assembly (26) and imaging of vimentin filaments in cells (27), we concluded that isolated expression of an amino-terminal fragment of vimentin lacking the tail region would effectively disrupt vimentin filaments. We engineered a stop codon at amino acid 134 of a GFP-vimentin expression vector, yielding a fragment (GFP-Vim-DN) that contains only the head domain of vimentin and a portion of the rod 1A domain, but lacks any of the tail sequence that is essential for vimentin filament assembly (Figure 6A). Both full-length GFP-vimentin and the GFP-Vim-DN fragment continue to be recognized by an amino-terminal vimentin antibody and GFP antibody, as well as displaying the expected molecular weight shift from fusion with GFP (Figure 6A – inset). Expression of GFP-Vim-DN in three independent invasive breast tumor cell lines (Hs578t, HCC1395 and MDA-MB-436) disrupts endogenous vimentin filaments (Figure 6B). Full-length GFP-vimentin integrates into filaments without disrupting endogenous vimentin. Cotransfection with a membrane-localized red fluorescent protein (pmRFP-Mem) allowed blinded microtentacle scoring in live cells and showed that GFP-Vim-DN significantly reduced microtentacle frequencies in each invasive cell line when compared to full-length GFP-Vim (P<0.001, t-test). Reducing vimentin expression with siRNA was not as effective as GFP-Vim-DN at reducing microtentacle frequencies. However, siRNA failed to fully eliminate vimentin, even after 6 days (Supplementary Figure 3). Interestingly, blotting with a pan-intermediate filament antibody indicated that as vimentin levels decreased, a new intermediate filament protein of ~65kDa increased, suggesting a compensatory response to siRNA-mediated vimentin reduction. Such a compensatory mechanism has been proposed for why vimentin knockout mice are viable and phenotypically normal (28), and illustrates the potential limitations of siRNA-mediated downregulation of such an abundant gene with numerous redundant family members. Nevertheless, expression of GFP-Vim-DN disrupted endogenous vimentin filaments within one day and provides genetic evidence that vimentin directly supports the molecular mechanism underlying microtentacles in detached breast tumor cells.

Discussion

Cytoskeletal rearrangements, release of cell-cell contacts, and loss of organized tissue architecture are hallmarks of metastatic progression (29). We previously reported that detached mammary epithelial cells display novel membrane protrusions enriched in detyrosinated α-tubulin; that we have termed tubulin microtentacles (mcTN) (10). Continuing our investigation into the occurrence of such microtentacles using a panel of breast carcinoma cells has revealed a marked increase in both microtentacle extension and frequency in more invasive tumor lines. Our data showing colocalization of vimentin with Glu-tubulin in microtentacles, the extensive microtentacles formed in cells with high vimentin expression and the inhibition of microtentacles with dominant negative vimentin or compounds targeting vimentin assembly, all support a model in which structural coordination of Glu-tubulin and vimentin underlie the striking morphological abnormalities we observe in detached breast tumor cells.

Our data also indicate that microtentacles in detached cells are distinct from other actin-based structures in attached cells, such as invadopodia or podosomes (30), which are inhibited by actin-destablizing agents such as Latrunculin-A or Cytochalasin-D. In contrast, microtentacles are enhanced by actin disruption and appear to become more flexible, motile, and longer (Figure 1B). This supports a model in which inward contraction of the cell’s cortical actin counteracts the mechanical forces exerted outward by filaments such as MTs and vimentin, and we are currently examining this repressive role for cortical actin in detail (Balzer, E.M. et al., manuscript submitted). MT-based cilia are characteristically shorter and more highly organized. In addition, MT-based cilia are not known to depend on intermediate filament proteins and their characteristic beat remains unaffected by concentrations of okadaic acid that exceed those we used in our study (31). However, it is possible that tubulin microtentacles were mistakenly identified as such classic cytoskeletal structures in the past. Interestingly, a patient case study reported the occurrence of multiple, “abnormal” microtubule protrusions in an infiltrating mammary ductal carcinoma but remains uncharacterized (32).

Vimentin expression is a marker of the aggressive “basal-cell” subtype of breast tumor (33, 34) and upregulation of vimentin predicts metastatic progression and poor patient prognosis (35). Beyond breast cancer, vimentin is an established independent predictor of poor patient prognosis in many tumors, including cervical (36), thyroid (37), hepatocellular (38), pancreatic (39) and renal carcinomas (40). Our results indicate that cell lines with the highest microtentacle counts display reduced expression of cytokeratins and increased vimentin, a change which is also observed during the epithelial-to-mesenchymal transition (EMT) that is associated with tumor progression and poor patient prognosis (41, 42). Interestingly, vimentin is also strongly upregulated when tumor cells are exposed to hypoxia (43). Our current evidence supports a direct role for vimentin in the mechanism underlying microtentacles in detached breast tumor cells. Determining how this role for vimentin relates to the additional phenotypic and transcriptional changes that occur during EMT and hypoxia will certainly be an important focus in future studies. In this report, we primarily consider how physical properties of vimentin could support microtentacle extension and potentially provide a selective advantage to tumor cells during metastasis.

Vimentin filaments are far more resilient than microtubules and play an important role in maintaining the integrity and morphology of fibroblastic cells (44). Despite its stability, vimentin can rapidly reorganize in response to phsophorylation. Live cell imaging indicates that microtentacles are comprised of cytoskeletal elements with the structural stability to persist in suspension yet also remain dynamic enough to support rapid movement in response to the cellular microenvironment (Figures 1, ,55 and Supplemental Movies). Phosphatases associated with vimentin promote filament stability and regulate binding ablility to IF-associated proteins, such as MTs (45). Furthermore, vimentin is rapidly hyperphosphorylated and disassembled after treatment with specific inhibitors of type 1 and 2A phosphatases, providing evidence that vimentin is a major target of PP1 and PP2A activity (23, 24).

There is strong evidence that vimentin and stabilized MTs are connected via shared associated proteins such as kinesin motor proteins (46), microtubule associated proteins (MAPs), and intermediate filament associated proteins (IFAPs). Ongoing investigation in our laboratory indicates that kinesins are involved in the microtentacle motility when cells are detached (Yoon, J. et al., manuscript in preparation). Kinesin-dependent crosslinking with vimentin could reinforce stabilized microtubules to allow the plasma membrane deformations that we observe during microtentacle extension. Contraction of the network of cortical actin filaments that lie beneath the plasma membrane usually provides an inward force that counteracts the outward expansion of microtubules from the cell center. The resulting balance of actin and microtubule forces stabilizes cells and is termed tensegrity (47). The actin cortex may therefore provide a physical barrier to microtubules, which are relatively easily broken when encountering compressive stress (48). However, tension and rigidity in the actin cortex decrease when cells are detached, which may partially remove this barrier (49). In addition, compelling recent studies trapping detached breast tumor cells with optical tweezers shows that cell lines with higher metastatic potential have greater flexibility in their actin cortex (50). This inherent weakness in the actin cortex of metastatic breast tumor cells may explain the greater microtentacle extension of invasive breast tumor cell lines, even without actin depolymerization (Figure 1). Given the interest in cytoskeletally-directed therapies for breast cancer, we are currently examining how the counteracting forces of stabilized microtubules and the actin cortex regulate microtentacle extension in breast tumor cells (Balzer, E.M. et al, submitted manuscript).

Based on our results, we propose that upon detachment, vimentin aligns with stable MTs via associated proteins to provide a flexible scaffold to Glu-enriched microtubles which allows microtentacles to protrude at great length from the cell body. The shorter, less frequent microtentacles observed in non-vimentin expressing, less invasive cell lines likely rely on the population of stable MTs but lack the increased resilience and strength of vimentin filaments (48). Disruption of vimentin filaments with either PP1/PP2A inhibitors or dominant-negative mutant vimentin likely promotes the collapse of Glu-MTs and ultimate deformation of the microtentacles.

Research models that involve studying attached cells in culture have limitations when investigating critical steps in the process of metastasis. While we continue to pursue the finctional role of tubulin microtentacles in metastasis, the dramatic morphological differences observed in detached breast tumor cell lines are compelling. Intriguing in vivo evidence exists that a yet-unidentified, tubulin-based (not actin-based) mechanism promotes the binding of circulating tumor cells to the vascular endothelium (11). It will therefore be important to determine whether the increased microtentacles in metastatic breast tumor cell lines provide an advantage for successful reattachment and extravasation following dissemination from the primary tumor site. A greater understanding of the foundation and activity of such extensive tubulin microtentacles displayed by invasive carcinoma cells may present an intriguing new target for cancer therapy.

Supplementary Material

S.video.1

Supplemental Movie 1:

GFP-Membrane transfected MCF10A detached for 30min in a low attachment plate, untreated. 1 frame/2sec, 5× speed.

S.video.2

Supplemental Movie 2:

GFP-Membrane transfected Bt-20 detached for 30min in a low attachment plate, untreated. 1 frame/2sec, 5× speed.

S.video.3

Supplemental Movie 3:

GFP-Membrane transfected MDA-436 detached for 30min in a low attachment plate, untreated. 1 frame/2sec, 5× speed.

S.video.4

Supplemental Movie 4:

GFP-Membrane transfected MCF10A detached for 30min in a low attachment plate, 5μM Latrunculin-A treated. 1 frame/2sec, 5× speed.

S.video.5

Supplemental Movie 5:

GFP-Membrane transfected Bt-20 detached for 30min in a low attachment plate, 5μM Latrunculin-A treated. 1 frame/2sec, 5× speed.

S.video.6

Supplemental Movie 6:

GFP-Membrane transfected MDA-436 detached for 30min in a low attachment plate, 5μM Latrunculin-A treated. 1 frame/2sec, 5× speed.

S.video.7

Supplemental Movie 7:

MDA-436 loosely attached to glass with active microtentacles, untreated. (1 frame/30 sec., 200× speed). Microtentacles remain active throughout time lapse.

S.video.8

Supplemental Movie 8:

MDA-436 loosely attached to glass with active microtentacles, treated with 5nM Calyculin-A. (1 frame/30 sec., 200× speed). Microtentacles shorten and slow considerably by 5 seconds into movie (20 min elapsed time after drug treatment).

Supp.Fig.1

Supplemental Figure 1:

Individual reattachment efficiency plots (N=2, N=3) of MCF10A over uncoated or laminin coated surfaces, untreated (An external file that holds a picture, illustration, etc.
Object name is nihms188281ig1.jpg) or in the presence of Cal-A (5μM, An external file that holds a picture, illustration, etc.
Object name is nihms188281ig2.jpg) or OKA (1μM, An external file that holds a picture, illustration, etc.
Object name is nihms188281ig3.jpg).

Supp.Fig.2

Supplemental Figure 2:

Individual reattachment efficiency plots (N=2, N=3) of MDA-436 over uncoated or laminin coated surfaces, untreated (An external file that holds a picture, illustration, etc.
Object name is nihms188281ig1.jpg) or in the presence of Cal-A (5μM, An external file that holds a picture, illustration, etc.
Object name is nihms188281ig2.jpg) or OKA (1μM, An external file that holds a picture, illustration, etc.
Object name is nihms188281ig3.jpg).

Supp.Fig.3

Supplemental Figure 3:

MDA-MB-436 were transfected with either a non-silencing control (NS) siRNA or siRNA vimentin (siVim). (A) At 6d post-transfection, the level of vimentin expression is significantly decreased as shown by Western blot while detection with a PAN-IF antibody shows an unidentified ~ 65kD IF that increases in expression while vimentin decreases. (B) Microtentacle counts in three independent experiments were performed in MDA-MB-436 GFP-Mem+ cells 6d post-transfection of either NS or siVim. There was no statistically significant change in the frequency of microtentacles in the cell population between the NS control and the siVim. (C) Immunofluorescence of attached MDA-MB-436 at 6d post-transfection of siVim shows reduced vimentin expression and organization in the cell population, but not complete silencing.

Acknowledgments

This work is supported by a Howard Temin career award (K01-CA096555) and 1R01CA124704-01 from the National Cancer Institute, a Breast Cancer Idea Award from the USA Medical Research and Materiel Command (BC061047) and a Cigarette Restitution Fund Cancer Research Grant (CH 649 CRF) from the State of Maryland Department of Health and Mental Hygiene. We thank Georges Lutfalla for kindly sharing the membrane-localized RFP expression vector.

ABBV

PR
Phenol Red
OKA
Okadaic Acid
Cal-A
Calyculin A
LA
Latrunculin A
CHX
Cycloheximide
Vim
Vimentin
CytoK
Cytokeratin
Glu
Glu (detyrosinated) tubulin
BF
Brightfield
Veh
Vehicle
DIC
Differential interference contrast
GFP
Green Fluorescent Protein
PP1/PP2A
Protein Phosphatase
ECM
Extracellular Matrix

References

1. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12:895–904. [PubMed]
2. Wittekind C, Neid M. Cancer invasion and metastasis. Oncology. 2005;69 (Suppl 1):14–6. [PubMed]
3. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679–95. [PubMed]
4. Wolf K, Friedl P. Molecular mechanisms of cancer cell invasion and plasticity. Br J Dermatol. 2006;154 (Suppl 1):11–5. [PubMed]
5. Yamauchi K, Yang M, Jiang P, et al. Real-time in vivo dual-color imaging of intracapillary cancer cell and nucleus deformation and migration. Cancer Res. 2005;65:4246–52. [PubMed]
6. Tsuji K, Yamauchi K, Yang M, et al. Dual-color imaging of nuclear-cytoplasmic dynamics, viability, and proliferation of cancer cells in the portal vein area. Cancer Res. 2006;66:303–6. [PubMed]
7. Martin SS, Vuori K. Regulation of Bcl-2 proteins during anoikis and amorphosis. Biochim Biophys Acta. 2004;1692:145–57. [PubMed]
8. Martin SS, Ridgeway AG, Pinkas J, et al. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene. 2004;23:4641–5. [PubMed]
9. Martin SS, Leder P. Human MCF10A mammary epithelial cells undergo apoptosis following actin depolymerization that is independent of attachment and rescued by Bcl-2. Mol Cell Biol. 2001;21:6529–36. [PMC free article] [PubMed]
10. Whipple RA, Cheung AM, Martin SS. Detyrosinated microtubule protrusions in suspended mammary epithelial cells promote reattachment. Exp Cell Res. 2007;313:1326–36. [PMC free article] [PubMed]
11. Korb T, Schluter K, Enns A, et al. Integrity of actin fibers and microtubules influences metastatic tumor cell adhesion. Exp Cell Res. 2004;299:236–47. [PubMed]
12. Barra HS, Arce CA, Argarana CE. Posttranslational tyrosination/detyrosination of tubulin. Mol Neurobiol. 1988;2:133–53. [PubMed]
13. Webster DR, Gundersen GG, Bulinski JC, Borisy GG. Assembly and turnover of detyrosinated tubulin in vivo. J Cell Biol. 1987;105:265–76. [PMC free article] [PubMed]
14. Mialhe A, Lafanechere L, Treilleux I, et al. Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis. Cancer Res. 2001;61:5024–7. [PubMed]
15. Kato C, Miyazaki K, Nakagawa A, et al. Low expression of human tubulin tyrosine ligase and suppressed tubulin tyrosination/detyrosination cycle are associated with impaired neuronal differentiation in neuroblastomas with poor prognosis. Int J Cancer. 2004;112:365–75. [PubMed]
16. Soucek K, Kamaid A, Phung AD, et al. Normal and prostate cancer cells display distinct molecular profiles of alpha-tubulin posttranslational modifications. Prostate. 2006;66:954–65. [PubMed]
17. Khawaja S, Gundersen GG, Bulinski JC. Enhanced stability of microtubules enriched in detyrosinated tubulin is not a direct function of detyrosination level. J Cell Biol. 1988;106:141–9. [PMC free article] [PubMed]
18. Gurland G, Gundersen GG. Stable, detyrosinated microtubules function to localize vimentin intermediate filaments in fibroblasts. J Cell Biol. 1995;131:1275–90. [PMC free article] [PubMed]
19. Yoon M, Moir RD, Prahlad V, Goldman RD. Motile properties of vimentin intermediate filament networks in living cells. J Cell Biol. 1998;143:147–57. [PMC free article] [PubMed]
20. Ball EH, Singer SJ. Association of microtubules and intermediate filaments in normal fibroblasts and its disruption upon transformation by a temperature-sensitive mutant of Rous sarcoma virus. Proc Natl Acad Sci U S A. 1981;78:6986–90. [PubMed]
21. Pruss RM, Mirsky R, Raff MC, Thorpe R, Dowding AJ, Anderton BH. All classes of intermediate filaments share a common antigenic determinant defined by a monoclonal antibody. Cell. 1981;27:419–28. [PubMed]
22. Campbell RE, Tour O, Palmer AE, et al. A monomeric red fluorescent protein. Proc Natl Acad Sci U S A. 2002;99:7877–82. [PubMed]
23. Eriksson JE, He T, Trejo-Skalli AV, et al. Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J Cell Sci. 2004;117:919–32. [PubMed]
24. Lee WC, Yu JS, Yang SD, Lai YK. Reversible hyperphosphorylation and reorganization of vimentin intermediate filaments by okadaic acid in 9L rat brain tumor cells. J Cell Biochem. 1992;49:378–93. [PubMed]
25. Mooney DJ, Langer R, Ingber DE. Cytoskeletal filament assembly and the control of cell spreading and function by extracellular matrix. J Cell Sci. 1995;108:2311–20. [PubMed]
26. Traub P, Scherbarth A, Wiegers W, Shoeman RL. Salt-stable interaction of the amino-terminal head region of vimentin with the alpha-helical rod domain of cytoplasmic intermediate filament proteins and its relevance to protofilament structure and filament formation and stability. J Cell Sci. 1992;101 (Pt 2):363–81. [PubMed]
27. McCormick MB, Kouklis P, Syder A, Fuchs E. The roles of the rod end and the tail in vimentin IF assembly and IF network formation. J Cell Biol. 1993;122:395–407. [PMC free article] [PubMed]
28. Moisan E, Chiasson S, Girard D. The intriguing normal acute inflammatory response in mice lacking vimentin. Clin Exp Immunol. 2007;150:158–68. [PubMed]
29. Gotzmann J, Mikula M, Eger A, et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res. 2004;566:9–20. [PubMed]
30. Yamaguchi H, Pixley F, Condeelis J. Invadopodia and podosomes in tumor invasion. Eur J Cell Biol. 2006;85:213–8. [PubMed]
31. Sutto Z, Conner GE, Salathe M. Regulation of human airway ciliary beat frequency by intracellular pH. J Physiol. 2004;560:519–32. [PubMed]
32. Reilova-Velez J, Seiler MW. Abnormal cilia in a breast carcinoma. An ultrastructural study. Arch Pathol Lab Med. 1984;108:795–7. [PubMed]
33. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol. 2006;60:1006–12. [PMC free article] [PubMed]
34. Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006;42:3149–56. [PubMed]
35. Domagala W, Striker G, Szadowska A, Dukowicz A, Harezga B, Osborn M. p53 protein and vimentin in invasive ductal NOS breast carcinoma--relationship with survival and sites of metastases. Eur J Cancer. 1994;30A:1527–34. [PubMed]
36. Gilles C, Polette M, Piette J, et al. Vimentin expression in cervical carcinomas: association with invasive and migratory potential. J Pathol. 1996;180:175–80. [PubMed]
37. Vasko V, Espinosa AV, Scouten W, et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A. 2007;104:2803–8. [PubMed]
38. Hu L, Lau SH, Tzang CH, et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene. 2004;23:298–302. [PubMed]
39. Javle MM, Gibbs JF, Iwata KK, et al. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 2007;14:3527–33. [PubMed]
40. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005;173:1496–501. [PubMed]
41. Domagala W, Lasota J, Dukowicz A, et al. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol. 1990;137:1299–304. [PubMed]
42. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res. 2005;11:8006–14. [PubMed]
43. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003;63:1138–43. [PubMed]
44. Goldman RD, Khuon S, Chou YH, Opal P, Steinert PM. The function of intermediate filaments in cell shape and cytoskeletal integrity. J Cell Biol. 1996;134:971–83. [PMC free article] [PubMed]
45. Inagaki M, Nishi Y, Nishizawa K, Matsuyama M, Sato C. Site-specific phosphorylation induces disassembly of vimentin filaments in vitro. Nature. 1987;328:649–52. [PubMed]
46. Prahlad V, Yoon M, Moir RD, Vale RD, Goldman RD. Rapid movements of vimentin on microtubule tracks: kinesin-dependent assembly of intermediate filament networks. J Cell Biol. 1998;143:159–70. [PMC free article] [PubMed]
47. Ingber DE. Tensegrity II. How structural networks influence cellular information processing networks. J Cell Sci. 2003;116:1397–408. [PubMed]
48. Janmey PA, Euteneuer U, Traub P, Schliwa M. Viscoelastic properties of vimentin compared with other filamentous biopolymer networks. J Cell Biol. 1991;113:155–60. [PMC free article] [PubMed]
49. Heidemann SR, Kaech S, Buxbaum RE, Matus A. Direct observations of the mechanical behaviors of the cytoskeleton in living fibroblasts. J Cell Biol. 1999;145:109–22. [PMC free article] [PubMed]
50. Guck J, Schinkinger S, Lincoln B, et al. Optical deformability as an inherent cell marker for testing malignant transformation and metastatic competence. Biophys J. 2005;88:3689–98. [PubMed]